SRTS

SRTS

USD

Sensus Healthcare Inc. Common Stock

$4.740+0.080 (1.717%)

Reaalajas hind

Healthcare
Meditsiiniseadmed
Ameerika Ühendriigid

Hinnagraafik

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$4.660

Kõrge

$4.785

Madal

$4.640

Maht

0.00M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

78.2M

Tööstusharu

Meditsiiniseadmed

Riik

United States

Kauplemisstatistika

Keskmine maht

0.27M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $3.35Praegune $4.740Kõrge $9.329

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 23. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

SRTS (Sensus Healthcare Inc. Common Stock): What's Happening and What to Watch For

Stock Symbol: SRTS Generate Date: 2025-04-23 02:14:18

Alright, let's break down what's been going on with Sensus Healthcare stock, SRTS, based on the latest info we've got. Think of this as looking at the puzzle pieces – the news, the price chart, and some predictions – to see what picture they paint.

Recent News Buzz: A Vote of Confidence

So, the main piece of news popping up is from HC Wainwright & Co. An analyst there, Yi Chen, basically said, "Yep, still like this stock." They reiterated their "Buy" rating and kept their price target right at $12.

What does that mean in plain English? An analyst giving a "Buy" rating thinks the stock is a good investment right now. A price target is where they believe the stock could trade in the future, often over the next year or so. Keeping it at $12 suggests they haven't changed their positive view on the company's potential, even if the stock price has been lower lately. This news is definitely a positive signal, a vote of confidence from someone who studies the company closely.

Price Check: A Bumpy Ride, Then Sideways

Looking at the stock's journey over the last few months, it's been quite a ride. Back in late January, it was hanging around $7. Then, in early February, it shot up pretty dramatically, even hitting over $9 briefly, before taking a really sharp nosedive down into the $5-$6 range. That was a wild swing!

Since that big drop in February, the price has mostly been grinding sideways or drifting slightly lower, generally staying between $4.50 and $5. The trading volume hasn't been huge most days, which isn't uncommon for smaller companies like this one.

The last few days show the stock trading right around the $4.50 to $4.60 mark.

Now, let's peek at those AI predictions for the very near future. The AI model is forecasting small but positive percentage increases for today and the next couple of days: +1.30% today, +3.12% tomorrow, and +4.62% the day after. This suggests the AI sees some potential for a short-term upward nudge from the current levels.

Putting It Together: What Might Be Next?

Okay, let's connect the dots. We have a positive analyst rating with a high price target ($12), recent price action that's been weak and trading much lower than that target, and an AI prediction that sees small upward moves coming soon.

Based on this mix, the apparent near-term leaning seems cautiously positive, driven more by the forward-looking analyst view and the AI's short-term forecast than the recent price history. The stock has been beaten down significantly from its early February peak, and the analyst thinks it's worth much more.

  • Potential Entry Consideration: If someone were considering getting into this stock, the current price area, hovering around $4.50-$4.60, looks interesting because it's close to a level ($4.44 - $4.51) that some analysis points to as potential support or an entry zone. It's also way below the analyst's target. Buying near recent lows or identified support levels is a common strategy to manage risk.
  • Potential Exit/Stop-Loss Consideration: Managing risk is super important. If you were to buy, setting a stop-loss order below a recent low or a key support level could help limit potential losses if the stock keeps falling. The recommendation data suggests $4.04 as a possible stop-loss point. On the flip side, if the stock does move up, the recommendation data points to $4.90 as a potential take-profit level – maybe a first target to lock in some gains. Remember, the analyst target is much higher at $12, but that's likely a longer-term view.

Company Context: What Sensus Does

Just a quick reminder about the company itself: Sensus Healthcare makes and sells medical devices, specifically radiation therapy systems used mainly for treating skin cancers and other skin conditions. They also have some other related products. They sell these to places like dermatology practices and hospitals. Knowing this helps understand why news related to healthcare, medical devices, or cancer treatment could impact them. It's also a relatively small company with a market cap around $76 million and lower average trading volume, which can sometimes mean bigger price swings.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock investing involves risk, and you could lose money. Always do your own thorough research or consult with a qualified financial advisor before making any investment decisions.

Seotud uudised

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Sensus Healthcare, Maintains $12 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Sensus Healthcare with a Buy and maintains $12 price target.

Vaata rohkem
HC Wainwright & Co. Reiterates Buy on Sensus Healthcare, Maintains $12 Price Target

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 27. apr 2025, 17:35

LangevNeutraalneTõusev

71.0% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
VäärtusKasv
Kauplemisjuhend

Sisenemispunkt

$4.73

Võta kasum

$5.24

Peata kahjum

$4.27

Põhitegurid

PDI 22.1 on MDI 13.5 kohal ADX-iga 16.8, mis viitab tõusutrendile
Praegune hind on tugitasemele ($4.70) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
MACD 0.0091 on signaalijoone 0.0047 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.